At the ongoing J.P. Morgan Healthcare Conference, Inspire Medical Systems boasted a five-year revenue set to grow at a CAGR of more than 50%, with $912m in 2025 and a projected $1.003bn–1.013bn in 2026.
A key highlight of Inspire Medical Systems’ presentation was the launch of its latest high-performing Inspire V product, which was first introduced in May 2025. Inspire V is an upper airway stimulation system used to treat moderate-to-severe obstructive sleep apnoea. Inspire V works by utilising a surgically implanted neurostimulator that provides a signal to the hypoglossal nerve to maintain an open airway for patients who may not tolerate continuous positive airway pressure (CPAP) machines.
Go deeper with GlobalData
Access deeper industry intelligence
Experience unmatched clarity with a single platform that combines unique data, AI, and human expertise.
Additional takeaways of the presentation include mentions of clinical trials in Singapore showing a 20% reduction in surgical times and 100% success in implantations. Moreover, long-term cardiovascular outcomes indicate that Inspire therapy is a more effective method of reducing cardiovascular disease compared to CPAP machines. Currently, Inspire Medical Systems has treated approximately 125,000 patients, but the company anticipates that there are approximately 500,000 eligible patients for its product line, presenting an opportunity worth more than $10bn.
Inspire Medical Systems’ growth strategy hinges on ensuring strong clinical outcomes, driving up manufacturing capabilities, improving customer experience, investing in R&D (namely the development of Inspire VI and VII), promoting consumer awareness, and expanding further into international markets.
Furthermore, ongoing Medicare reimbursement developments involving increased approved payment rates are expected to result in the increased adoption of these device types, driving sales for this space and bolstering Inspire’s market position going forward.
Heading into 2026, Inspire has demonstrated favourable growth factors based on current revenue projections and the efficacy of its product line, which is being increasingly supported through clinical trial outcomes. While Inspire Medical Systems only focuses on one area of medical devices, specifically neurostimulation devices focused on treating obstructive sleep apnoea, the company is the leader in this space. The current quality of Inspire Medical Systems’ product development and the growing awareness of the benefits of this technology are likely to sustain steady growth for the company.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalData“Sign up here to receive daily updates on the latest healthcare industry trends emerging from the JP Morgan Healthcare conference 2026. Sign up here to receive a comprehensive report after the conference.”
